FindTrial
Sign In

Assessing the relationship between the dose of vitamin B12 administered and its absorption in the intestine in normal humans

Dose-dependency of vitamin B12 on its intestinal absorption in normal humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043417
Enrollment
9
Registered
2022-06-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Stable isotope-labelled vitamin B12 ([13C]-cyanocobalamin ): 3 doses of [13C]-cyanocobalamin,i.e, 2.5mcg,5mcg and 10mcg , will be given to each participant after dissolving in 2ml dis

Sponsors

Clinical Research Centre Department of Physiology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Apparently healthy participants between the ages of 18 and 40. 2. BMI 3. Normal plasma total B12 level 4. Normal active B12 or Holo-TC concentration

Exclusion criteria

Exclusion criteria: 1. Participants with existing vitamin B12 deficiency 2. Participants with folate deficiency on clinical supplementation 3. Participants with end-stage renal disease or on haemodialysis, atrophic gastritis, history of alcoholism, use of drugs (methotrexate, antacids, and metformin) known to affect B12 absorption, and on antibiotics/medication known to influence GI motility.

Design outcomes

Primary

MeasureTime frame
Vitamin B12 bioavailabilityTimepoint: 7 hours after administration of Vitamin B12 dose—

Secondary

MeasureTime frame
Decrease in the bioavailability of vitamin B12 with increase in dose administered(2.5 , 5 and 10 mcg)Timepoint: 7 hours after administration of vitamin B12 dose—

Countries

India

Contacts

Public ContactPoorvikha S

St. Johns Medical College

a.kurpad@sjri.res.in9686512233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026